company background image
ATOS

Atossa TherapeuticsNasdaqCM:ATOS Stock Report

Market Cap

US$288.7m

7D

-3.0%

1Y

31.0%

Updated

28 Nov, 2021

Data

Company Financials +
ATOS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ATOS Stock Overview

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases.

Atossa Therapeutics Competitors

Natera

NasdaqGS:NTRA

US$9.0b

Roche Holding

SWX:ROG

CHF310.3b

Thermo Fisher Scientific

NYSE:TMO

US$251.7b

Illumina

NasdaqGS:ILMN

US$57.8b

Price History & Performance

Summary of all time highs, changes and price drops for Atossa Therapeutics
Historical stock prices
Current Share PriceUS$2.28
52 Week HighUS$9.80
52 Week LowUS$0.81
Beta2.04
1 Month Change-11.28%
3 Month Change-35.41%
1 Year Change31.03%
3 Year Change100.00%
5 Year Change-90.87%
Change since IPO-99.74%

Recent News & Updates

Sep 22

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Atossa Therapeutics is clinical-stage biotech whose stock has trended a highly volatile path during the last one-year period. In addition to breast cancer research, where the company has been involved for years, it also focuses on producing nasal drops and inhalation therapy for combating COVID-19. Despite so many vaccines being available, alternatives still make sense in view of the coronavirus mutating rapidly and the limited immunity period conferred by current ones. There is sufficient cash to fund steadily rising R&D expenses. Currently below the $4 level, with its proprietary compounds constituting valuable assets, the company makes for investment in this COVID world.

Jul 17
Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Jun 30

Atossa Therapeutics: Hope Springs Eternal

After a blistering June rally, we see a temporary top here probably back to around the $4 level. Implied volatility remains significantly elevated. We are going to get our move sooner rather than later. We are controlling risk by rolling puts out in time. Significant upside potential due to recent results remains.

Jun 16

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Atossa Therapeutics (ATOS) is set to be added to the Russell 2000 and Russell 3000 Indexes, effective after the U.S. market opens on June 28, 2021. “Atossa’s inclusion in both the Russell 2000 and Russell 3000 Indexes present an important opportunity for us to further expand Atossa’s awareness among a broader group of investors, which we expect will also further enhance its liquidity,” said Kyle Guse, Atossa’s CFO and General Counsel.

Shareholder Returns

ATOSUS BiotechsUS Market
7D-3.0%0.4%-2.7%
1Y31.0%5.3%21.3%

Return vs Industry: ATOS exceeded the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: ATOS exceeded the US Market which returned 21.3% over the past year.

Price Volatility

Is ATOS's price volatile compared to industry and market?
ATOS volatility
ATOS Average Weekly Movement8.8%
Biotechs Industry Average Movement8.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: ATOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ATOS's weekly volatility has decreased from 20% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20087Steve Quayhttps://www.atossatherapeutics.com

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer.

Atossa Therapeutics Fundamentals Summary

How do Atossa Therapeutics's earnings and revenue compare to its market cap?
ATOS fundamental statistics
Market CapUS$288.70m
Earnings (TTM)-US$27.76m
Revenue (TTM)n/a

0.0x

P/S Ratio

-10.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATOS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$27.76m
Earnings-US$27.76m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ATOS perform over the long term?

See historical performance and comparison

Valuation

Is Atossa Therapeutics undervalued compared to its fair value and its price relative to the market?

2.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ATOS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ATOS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ATOS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ATOS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATOS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATOS is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Atossa Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

78.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATOS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ATOS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ATOS's is expected to become profitable in the next 3 years.

Revenue vs Market: ATOS is forecast to have no revenue next year.

High Growth Revenue: ATOS is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATOS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Atossa Therapeutics performed over the past 5 years?

-20.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATOS is currently unprofitable.

Growing Profit Margin: ATOS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATOS is unprofitable, and losses have increased over the past 5 years at a rate of 20% per year.

Accelerating Growth: Unable to compare ATOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATOS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: ATOS has a negative Return on Equity (-16.45%), as it is currently unprofitable.


Financial Health

How is Atossa Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ATOS's short term assets ($143.0M) exceed its short term liabilities ($1.7M).

Long Term Liabilities: ATOS has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: ATOS is debt free.

Reducing Debt: ATOS has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATOS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ATOS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.8% each year


Dividend

What is Atossa Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATOS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATOS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Steve Quay (70 yo)

12.58yrs

Tenure

US$2,936,284

Compensation

Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD2.94M) is above average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ATOS's management team is seasoned and experienced (7.3 years average tenure).


Board Members

Experienced Board: ATOS's board of directors are seasoned and experienced ( 10 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1106.8%.


Top Shareholders

Company Information

Atossa Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Atossa Therapeutics, Inc.
  • Ticker: ATOS
  • Exchange: NasdaqCM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$288.703m
  • Shares outstanding: 126.62m
  • Website: https://www.atossatherapeutics.com

Number of Employees


Location

  • Atossa Therapeutics, Inc.
  • 107 Spring Street
  • Seattle
  • Washington
  • 98104
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/28 23:03
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.